Contact
searchSearch
HMP Global
Login

Journal of Clinical Pathways

From the Journal

From the Field
Bridging the Gap Between Oncologists and Payers: Impact of an EHR-Embedded CDS Tool in Oncology Clinical Pathway (OCP) Adherence
08/15/2025
Anna Bolha, MPAS, PA; Rebecca Maniago, PharmD, BCOP; Nina Sardesh; Taylor Dias-Foundas; James Roose, MA; Colin Harvey; Marcello Ricottone; Eric Weber; Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC; Brian Patrick Mulherin, MD; Andrew Hertler, MD, FACP; James Hamrick, MD, MPH
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers...
08/15/2025
Journal of Clinical Pathways
From the Field
Operationalizing Weight-Based Dosing of Pembrolizumab: Opportunities and Challenges
08/15/2025
Samyukta Mullangi, MD, MBA; Alphan Kirayoglu, MA; Amila Patel, PharmD; Robert J. Green, MD, MSCE; Keshav Goel, MS; James Gilmore, PharmD; Stephen Garrel Divers, MD
To curb the high cost of cancer care driven by flat-dose pricing of drugs like pembrolizumab, the American Oncology Network has implemented a suite of technological and workflow innovations that increased weight-based dosing, offering a...
To curb the high cost of cancer care driven by flat-dose pricing of drugs like pembrolizumab, the American Oncology Network has implemented a suite of technological and workflow innovations that increased weight-based dosing, offering a...
To curb the high cost of cancer...
08/15/2025
Journal of Clinical Pathways
Original Research
Cost Utility Analyses Demonstrating Support for Indication-Specific Pricing for the Targeted Therapy Bevacizumab
06/16/2025
John P. Geisler, MD, PharmD, MS; Nagadharshan Devendra, MD; Kelly J. Manahan, MD, MBA
This study evaluates how indication-specific pricing for bevacizumab in cervical and colon cancer could align with a $100 000 per quality adjusted life-year willingness-to-pay threshold.
This study evaluates how indication-specific pricing for bevacizumab in cervical and colon cancer could align with a $100 000 per quality adjusted life-year willingness-to-pay threshold.
This study evaluates how...
06/16/2025
Journal of Clinical Pathways
From the Field
Turning Pathways on Their Head: Deimplementation of Low-Value Treatment Regimens
04/15/2025
Sang Chau, PharmD, BCOP; Amy VanGalder, PharmD, BCOP; Garrick Wong, PharmD; Terra Wonsettler, PharmD, MBA; Emma Domico, MS; Andrew Hertler, MD, FACP
This study discusses how Evolent is tackling the rising costs of cancer treatment by actively reducing low-value oncology care through strategic interventions.
This study discusses how Evolent is tackling the rising costs of cancer treatment by actively reducing low-value oncology care through strategic interventions.
This study discusses how Evolent...
04/15/2025
Journal of Clinical Pathways
Perspectives
Taking the Garbage Out: Addressing AI Bias in Quality Measurement
12/02/2024
Maggie Dietrick, MPH; Palak Patel, MHA; Tom Valuck, MD, JD
This article explores the use of artificial intelligence (AI) in health care quality measurement and tactics to mitigate bias in AI-enhanced measurement.
This article explores the use of artificial intelligence (AI) in health care quality measurement and tactics to mitigate bias in AI-enhanced measurement.
This article explores the use of...
12/02/2024
Journal of Clinical Pathways
From the Field
Cost and Clinical Implications of Utilizing Homologous Recombination Deficiency Status to Guide First-Line Maintenance Therapy Selection in Advanced Ovarian Cancer
12/02/2024
Daniel Simmons, PharmD, MS; Rebecca Stone, MD; James Ryan, MSc; Jigna Bhalla, PharmD; Kimmie McLaurin, MS
This study models the clinical outcomes and costs associated with utilizing an HRD biomarker-guided (BMG) approach to first-line AOC maintenance compared with a non-biomarker-guided (NBMG) approach.
This study models the clinical outcomes and costs associated with utilizing an HRD biomarker-guided (BMG) approach to first-line AOC maintenance compared with a non-biomarker-guided (NBMG) approach.
This study models the clinical...
12/02/2024
Journal of Clinical Pathways
Perspectives
Facing Cancer as a Chronic Disease: Shared Decision-Making at Critical Points in a Long Illness Journey
10/01/2024
Christine M. Wilson, MS; Gwen Darien; Kathleen D. Gallagher, MPH; Alan J. Balch, PhD, MSc
In this third installment of a three-part series on decision support tools and shared decision-making, Christine Wilson, MA, MS, and colleagues describe how patients with­in three diverse communities who are living with cancer understand and...
In this third installment of a three-part series on decision support tools and shared decision-making, Christine Wilson, MA, MS, and colleagues describe how patients with­in three diverse communities who are living with cancer understand and...
In this third installment of a...
10/01/2024
Journal of Clinical Pathways
Perspectives
Who Uses Pathways Around Care Management?
10/01/2024
Sheryl Riley, RN, OCN, CMCN; F. Randy Vogenberg, PhD, FASHP
This pilot study provides a brief literature review on users, uses, and a recent electronic survey to de­termine how users use clinical pathways along with their feedback around their value.
This pilot study provides a brief literature review on users, uses, and a recent electronic survey to de­termine how users use clinical pathways along with their feedback around their value.
This pilot study provides a...
10/01/2024
Journal of Clinical Pathways
From the Field
Bridging the Gap Between Oncologists and Payers: Impact of an EHR-Embedded CDS Tool in Oncology Clinical Pathway (OCP) Adherence
08/15/2024
Anna Bolha, MPAS, PA; Rebecca Maniago, PharmD, BCOP; Nina Sardesh; Taylor Dias-Foundas; James Roose, MA; Colin Harvey; Marcello Ricottone; Eric Weber; Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC; Brian Patrick Mulherin, MD; Andrew Hertler, MD, FACP; James Hamrick, MD, MPH
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers...
08/15/2024
Journal of Clinical Pathways
Perspectives
Individualized Care Through Treatment Pathways: Isn’t This an Oxymoron?
06/26/2024
Ray Page, DO, PhD, FACOI, FASCO
This article describes how congruent solutions for treatment options can be achieved if the objectives of precision medicine and treatment pathways are aligned.
This article describes how congruent solutions for treatment options can be achieved if the objectives of precision medicine and treatment pathways are aligned.
This article describes how...
06/26/2024
Journal of Clinical Pathways

KOL Insights

Golla Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
09/10/2025
Vishnukamal Golla, MD, MPH
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal...
09/10/2025
Journal of Clinical Pathways
Thawani Headshot
Videos
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
08/28/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
08/28/2025
Journal of Clinical Pathways
Wilfong Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/20/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/20/2025
Journal of Clinical Pathways
Henschel
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/13/2025
Rhonda Henschel, MBA
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/13/2025
Journal of Clinical Pathways
Arrowsmith Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/08/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/08/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Recognizing the Importance of Primary Care in Cancer Care Delivery
08/04/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the undervalued yet critical role of primary care in the health care ecosystem—especially in oncology—highlighting its impact on early detection,...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the undervalued yet critical role of primary care in the health care ecosystem—especially in oncology—highlighting its impact on early detection,...
In this episode of Breaking Down...
08/04/2025
Cancer Care Business Exchange
Videos
Driving Innovation in Care With Edward Arrowsmith, MD, and the Predictable Cost of Care Working Group
07/28/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
07/28/2025
Journal of Clinical Pathways
Chau and VanGalder Headshots
Videos
Understanding Clinical Pathways: Quality, Cost, and Collaboration
07/25/2025
Amy VanGalder, PharmD, BCOP; Sang Chau, PharmD, BCOP
Two oncology pharmacy leaders from Evolent discuss how clinical pathways—grounded in evidence and integrated with technology—are transforming cancer care by improving quality, reducing costs, and aligning with value-based care models.
Two oncology pharmacy leaders from Evolent discuss how clinical pathways—grounded in evidence and integrated with technology—are transforming cancer care by improving quality, reducing costs, and aligning with value-based care models.
Two oncology pharmacy leaders...
07/25/2025
Journal of Clinical Pathways
Videos
Driving Innovation in Care With Lalan Wilfong, MD, and the Predictable Cost of Care Working Group
07/25/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
07/25/2025
Journal of Clinical Pathways
Vogenberg Headshot
Videos
Forecasting Access: How Employers Can Strategize for High-Cost Therapies in a Volatile Landscape
07/21/2025
F. Randy Vogenberg, PhD, FASHP
Dr Randy Vogenberg explores how employers, providers, and manufacturers must collaborate more effectively to navigate the complex challenges of benefit design, patient access, and financial planning in the face of rapidly evolving and costly...
Dr Randy Vogenberg explores how employers, providers, and manufacturers must collaborate more effectively to navigate the complex challenges of benefit design, patient access, and financial planning in the face of rapidly evolving and costly...
Dr Randy Vogenberg explores how...
07/21/2025
Journal of Clinical Pathways

In the News

News
NRF2 Inhibition Emerges as a Promising Strategy to Halt Esophageal Cancer Spread
08/13/2025
Lisa Kuhns, PhD, MD
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a...
08/13/2025
Journal of Clinical Pathways
News
Palliative Care Use Rose 24% in Medicare Cancer Decedents, but Disparities Persist
08/12/2025
Hannah Musick
Specialty palliative care use among Medicare decedents with poor-prognosis cancers grew significantly between 2018 and 2023. The change is driven by outpatient services, telehealth, and advanced practice clinicians—yet older adults,...
Specialty palliative care use among Medicare decedents with poor-prognosis cancers grew significantly between 2018 and 2023. The change is driven by outpatient services, telehealth, and advanced practice clinicians—yet older adults,...
Specialty palliative care use...
08/12/2025
Journal of Clinical Pathways
News
Perioperative Durvalumab-FLOT Regimen Demonstrates Superior Efficacy Over FLOT Alone
08/06/2025
Juliet Gallagher
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in...
08/06/2025
Journal of Clinical Pathways
News
Specialized Teams Improve Safety as Immunotherapy Use Surges in Cancer Care
07/30/2025
Lisa Kuhns, PhD, MD
As immunotherapy continues to transform cancer treatment, multidisciplinary teams are proving essential for managing the potentially severe toxicities that accompany these therapies, according to an article published in the American Society...
As immunotherapy continues to transform cancer treatment, multidisciplinary teams are proving essential for managing the potentially severe toxicities that accompany these therapies, according to an article published in the American Society...
As immunotherapy continues to...
07/30/2025
Journal of Clinical Pathways
News
NCCN Launches Interactive NCCN Guidelines Navigator to Advance Cancer Care Usability
07/11/2025
Grace Taylor, MS, MA
Discover how the National Comprehensive Cancer Network’s (NCCN) new digital Guidelines Navigator is transforming cancer care delivery with smarter, faster, and more accessible clinical guidelines.
Discover how the National Comprehensive Cancer Network’s (NCCN) new digital Guidelines Navigator is transforming cancer care delivery with smarter, faster, and more accessible clinical guidelines.
Discover how the National...
07/11/2025
Journal of Clinical Pathways
News
Study Finds Key Risk Factors for Gastric Cancer in US Patients With Chronic Gastritis
07/11/2025
Lisa Kuhns, PhD, MD
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed...
07/11/2025
Journal of Clinical Pathways
News
Persistent Barriers in Gastric Cancer Care: GI Cancers Alliance Study
07/09/2025
Grace Taylor, MS, MA
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI...
07/09/2025
Journal of Clinical Pathways
News
Nivolumab-Based Regimens Extend Survival in Advanced Gastroesophageal Cancer Based on Molecular Biomarkers
06/25/2025
Lisa Kuhns, PhD, MD
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy...
06/25/2025
Journal of Clinical Pathways
News
Study Shows Improved Outcomes in Older Adults With Mantle Cell Lymphoma Following Adoption of New Therapies
06/16/2025
Juliet Gallagher
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large,...
06/16/2025
Journal of Clinical Pathways
News
Virtual Screening Programs Expand Access to Cancer Screening Nationwide
06/13/2025
Grace Taylor, MS, MA
Virtual, community-based cancer screening programs significantly improve access to early detection services, especially in underserved populations, according to a study presented at the ASCO Annual Meeting.
Virtual, community-based cancer screening programs significantly improve access to early detection services, especially in underserved populations, according to a study presented at the ASCO Annual Meeting.
Virtual, community-based cancer...
06/13/2025
Journal of Clinical Pathways

Quality Outlook

Blog
CPC+CBEx 2025 Abstracts: Business Models, Breakthrough Tools, and Data-Driven Decisions Driving the Future of Cancer Care
08/27/2025
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways...
08/27/2025
Journal of Clinical Pathways
Quality Outlook
Every Second Counts: the Impact of FDA’s Accelerated Approval Program
03/05/2025
Bridget Doherty, MPH, MS; Silas Martin, MS; Tom Valuck, MD, JD
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research...
03/05/2025
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
Winston Wong, PharmD
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Kendall Logan, MPH.
Quality Outlook
A Tale of Two States: Examining the Best and Worst Performing States for HPV Vaccination
02/12/2024
Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther; Tom Valuck, MD, JD
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a...
02/12/2024
Journal of Clinical Pathways
Theresa Schmidt headshot.
Quality Outlook
2024 Quality Outlook Revealed: Insights from 2023 Fall Conferences
02/02/2024
Tom Valuck, MD, JD; Erik Muther; Theresa Schmidt, MA, PMP, CSPO; Danny Bellet, MBA; Donna Dugan, PhD, MS; David Sloan, PhD
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the...
02/02/2024
Journal of Clinical Pathways
Anne Disalvo headshot
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Racial and Ethnic Disparities in HPV Vaccination
11/10/2023
Tom Valuck, MD, JD; Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a...
11/10/2023
Journal of Clinical Pathways
Anne DiSalvo.
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Geographic Disparities in HPV Vaccination
10/03/2023
Tom Valuck, MD, JD; Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part...
10/03/2023
Journal of Clinical Pathways
David Blaisdell, BA, Real Chemistry.
Quality Outlook
Enhancing Value-Based Oncology Care: What Has CMMI Learned From the OCM?
09/22/2023
David Blaisdell, BA; Tom Valuck, MD, JD
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about...
09/22/2023
Journal of Clinical Pathways
Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023
Tom Valuck, MD, JD; Jacqlyn Riposo, MBA
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use